CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today interim data for romidepsin (formerly known as depsipeptide, FK228), the Company’s novel histone deacetylase inhibitor, at the American Society of Hematology Annual Meeting held in Orlando, FL. Data were presented on two studies: a Gloucester-sponsored pivotal phase II trial of romidepsin for patients with treatment refractory cutaneous T-cell lymphoma (CTCL); and a phase II study sponsored by the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Gloucester.
